Waters BD Onclarity HPV assay is intended to remove barriers that prevent individuals from receiving routine cervical cancer screening.

The US FDA's approval of Waters' at-home cervical cancer screening kit marks a significant step in enhancing early detection and reducing fatalities. This move positively impacted Waters' stocks, ...

Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV ...

Waters unveils US FDA approved At-Home Cervical Cancer Screening Tool, Onclarity HPV: Our Bureau, Bengaluru Friday, April 10, 2026, 17:15 Hrs [IST] Waters Corporation announced th ...

Public health experts urge enhanced safety measures, independent evaluation, and comprehensive cervical cancer screening ...

Recent health sector developments include the US FDA's approval of Waters' cervical cancer screening kit, tightening ...

The life sciences and diagnostics company said Wednesday the regulator cleared its Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use.

Waters Corporation WAT shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV ...

Cancer Awareness, Prevention and Screening 5th Camp Marks World Health Day with strong police participation ...

In the Philippines, the battle against women’s cancers, specifically breast, cervical, and endometrial cancer, is defined by ...

Women’s cancers—such as breast, cervical and endometrial cancer—continue to pose a significant health challenge in the ...